Study design and participants

JC Jun Chen
TQ Tangkai Qi
LL Li Liu
YL Yun Ling
ZQ Zhiping Qian
TL Tao Li
FL Feng Li
QX Qingnian Xu
YZ Yuyi Zhang
SX Shuibao Xu
ZS Zhigang Song
YZ Yigang Zeng
YS Yinzhong Shen
YS Yuxin Shi
TZ Tongyu Zhu
HL Hongzhou Lu
ask Ask a question
Favorite

For this retrospective, single-center study, we recruited patients from Jan 20 to Feb 6, 2020, at Shanghai Public Health Clinical Center (SPHCC), Shanghai, China. SPHCC is the pointed hospital that treat COVID-19 for adults in Shanghai. All patients with COVID-19 enrolled in this study were diagnosed according to Chinese national guideline for COVID-19 diagnosis and treatment, as well as the World Health Organization interim guidance.4 The study was approved by Ethics Committee of SPHCC and informed consent was obtained from patients involved before data were collected retrospectively. Informed consent was waived for patients unable to obtain an informed consent (i.e., those discharged or died).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A